Investigational drug study for Treatment of Non-Small Cell Lung Cancer
In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.
Michael P. Kosty, M.D.
This study will test the safety of an experimental drug called atezolizumab given in combination with other chemotherapy drugs. Patients will receive 4 cycles of chemotherapy and undergo surgical removal of their tumor. Some patients may also receive an additional 16 cycles of chemotherapy with atezolizumab.
Be 18 years of age or older
Have resectable Stage II, IIA, or Select IIIB Non-small cell lung cancer
Have had any prior therapy for lung cancer, including chemotherapy or radiotherapy
Have had any major surgical procedure within 28 days prior to starting study treatment
Have any significant heart disease
Have a history of cancer other than lung cancer within the last 5 years
Be pregnant or nursing
Atezolizumab is an investigational immunotherapy drug that is designed to work with the body's own immune system. It may help to activate the immune response and stop a protein called PD-L1 from preventing the body's immune system from fighting cancer.